EGFR and ovarian carcinoma: The effect of EGFR-ERK pathway on cell survival, proliferation, motility and drug resistance has been extensively studied.47, 48 Considering AREG is the ligand of EGFR and the promotion effects of AREG on ovarian cancer stemness and drug resistance, we further investigated if miR-34c-5p inhibited ovarian cancer stemness and drug resistance through the AREG-EGFR-ERK axis.